An 8-fold increase in serum bile acids sounds like a toxicity flag, but in this case it is precisely the proof ProQR needed. Data released Wednesday from the Phase 1 multiple ascending dose study of AX-0810 show that deliberately blocking hepatic bile acid reuptake via NTCP modulation works as designed in humans, confirming the first clinical validation of ProQR’s Axiomer RNA editing platform. The 6 mg/kg cohort hit that 8-fold change in total serum bile acids, four times the 2-fold threshold ProQR had pre-specified as a meaningful indicator of NTCP engagement. The mechanism is counterintuitive but coherent: keeping conjugated bile acids in circulation, where the kidneys can clear them through urinary excretion, is what protects the liver from the toxic accumulation that drives cholestatic disease.
The design choices here matter clinically. AX-0810 edits the bile acid binding pocket of the NTCP protein while leaving its hormonal transport function intact, and the Phase 1 data confirmed no changes in circulating hormone levels, supporting functional selectivity. The drug is subcutaneously administered as a GalNAc-conjugated oligonucleotide, and pharmacokinetic data from the 22 evaluable participants across the 3 mg/kg and 6 mg/kg cohorts show an eight-week half-life, a profile that projects toward infrequent dosing. No serious adverse events and no pruritus were observed, which is notable given that elevated serum bile acids are themselves a known driver of itch in cholestatic conditions. The 9 mg/kg cohort data remain pending, and full 12-week follow-up across all three cohorts has not yet been reported.
The near-term strategic consequence of this readout is the acceleration of AX-0811, a next-generation NTCP-targeting oligonucleotide built with ProQR’s AI-enabled discovery engine. Preclinical modeling projects AX-0811 will achieve at least 4-fold higher RNA editing at lower doses, with a half-life exceeding three months. ProQR expects to file a Clinical Trial Application for AX-0811 in mid-2026 and anticipates initial human data in healthy volunteers before year-end. Biliary atresia, a severe pediatric liver disease where current management has long relied on off-label agents including ursodiol, which carries no FDA approval for this indication, is the planned Phase 2 target for the NTCP franchise.
The single marker worth tracking now is whether AX-0811’s CTA clears regulatory acceptance in time to generate healthy volunteer data by December 2026. If that timeline holds, ProQR will enter 2027 with two successive human datasets validating Axiomer-based NTCP editing, which transforms this from a platform proof-of-concept into a franchise with genuine clinical momentum in pediatric liver disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
